Phakic Intraocular Lens Implantation After Deep Anterior Lamellar Keratoplasty: Retrospective Case Series Analysis With Long-Term Follow-Up

Luísa Malheiro 1
João Coelho 1
Miguel Mesquita Neves 1, 2
Miguel Gomes 1, 2
Luís Oliveira 1, 2

1 Ophthalmology Department, Hospital de Santo António, Centro Hospitalar Universitário do Porto, Porto, Portugal; 2 Corneal Transplant Unit, Hospital de Santo António, Centro Hospitalar Universitário do Porto, Porto, Portugal

Purpose: To report outcomes of phakic intraocular lens (IOL) implantation after deep anterior lamellar keratoplasty (DALK) to correct high ametropia.

Setting: Centro Hospitalar Universitário do Porto, Portugal.

Methods: Retrospective case series with 11 eyes submitted to phakic IOL implantation after DALK. Main outcomes measured were uncorrected and corrected distance visual acuity (UDVA and CDVA), refractive error components, tomographic parameters and endothelial cell density (ECD). The minimum follow-up was 3 years for all cases.

Results: Mean ECD loss was 8.7±6.7% at 1 year, 13.1±8.6% at 3 years (n=11; p=0.016, p=0.007, respectively) and 14.0±20.4% at 5 years (n=5, p=0.212). Mean logMAR UDVA increased from 1.27±0.90logMAR preoperatively to 0.16±0.15logMAR postoperatively (p≤0.001) and no statistically significant differences were registered during follow-up. All patients gained at least 5 lines of UDVA. 54.5% of the eyes gained 1 line in CDVA postoperative and only one eye lost one CDVA line through follow-up. Efficacy and safety indexes at 1 and 3 years were 1.01–0.97 and 1.24–1.21, respectively. Mean spherical equivalent was reduced from −7.84±4.63 D preoperatively to −1.05±1.07 D postoperatively (p=0.001). Mean percentage of reduction in refractive cylinder and spherical error was 83.8±15.8% and 73.1±31.5%, respectively, p≤0.001 for both. In one eye there was a significantly gradual ECD loss over 5 years follow-up and the patient will be submitted to IOL explant.

Conclusion: Phakic IOLs were effective for correction high ametropia after DALK, showing high efficacy and safety indexes with stability over time. However, it was registered a continuing endothelial cell loss postoperatively, which assumed to be higher than those reported in eyes without DALK.

Keywords: phakic intraocular lens, deep anterior lamellar keratoplasty, endothelial cell density, visual outcomes, refractive outcomes

Introduction
Deep anterior lamellar keratoplasty (DALK) is the gold-standard keratoplasty technique for the treatment of keratoconus and other anterior lamellar corneal pathology not affecting the endothelium. Risk of graft rejection, postoperative complications and late endothelial cell density (ECD) decay is reduced when compared to traditional penetrating keratoplasty (PK). Nevertheless, differences between visual acuity, refractive errors and corneal astigmatism following DALK or PK are similar. 1–3

Postoperative uncorrected visual acuity after these procedures is often poor due to postoperative ametropia, especially high astigmatism. 4
Several options can be considered for the management of postoperative ametropia, ranging from conservative solutions such as spectacles or contact lenses, to corneal refractive surgery and intraocular surgical procedures.

The presence of anisometropia can limit the use of spectacles. Rigid gas-permeable contact lenses are effective in a high percentage of patients, but topographical irregularities, dry eye, poor manual dexterity and lack of motivation make contact lenses’ fitting a challenging process in some cases. Corneal refractive surgery with excimer laser photorefractive keratectomy (PRK) or LASIK can treat a great range of postoperative refractive error by corneal tissue ablation. However, the corneal graft thickness and the amount of ametropia and astigmatism suitable for correction limit the effectiveness of these procedures.

Intraocular surgical procedures with implantation of iris-fixated phakic intraocular lenses (IOLs) or posterior chamber IOLs can also be successfully used for surgical correction of high post-graft ametropia.

The Artisan® and Artiﬂex® lenses (Ophtec BV, Groningen, the Netherlands) are anterior chamber, iris-enclaved, phakic IOLs. These IOLs demonstrate reversibility, high optical quality, refractive predictability and stability. Some previous reports describe good postoperative results in the correction of ametropias after PK and DALK with these IOLs.

However, to the best of our knowledge, there are few reports regarding long-term results of corneal ECD loss and visual and refractive outcomes of phakic IOL implantation in patients who had previously undergone DALK.

The aim of this study was to report the long-term clinical outcomes of a case series of patients with phakic IOL implantation for correction of ametropia following DALK for keratoconus.

**Methods**

**Study Population**

Retrospective, noncomparative study with 11 eyes of 11 patients with keratoconus who underwent DALK with the big-bubble technique from February 2009 to June 2012 at Centro Hospitalar Universitário do Porto, Portugal. The patients were subsequently submitted to toric phakic IOL implantation for correction of ametropia.

All surgeries were performed by 2 surgeons, L.O and M.G, with extensive experience in the implantation of phakic IOLs.

Before phakic IOL implantation, the patients underwent routine ophthalmic examination, including manifest and cycloplegic refractions, evaluation of uncorrected distance visual acuity (UDVA) and distance corrected visual acuity (CDVA), slit-lamp examination, Goldmann applanation tonometry, gonioscopy, dilated fundus examination, corneal tomography and endothelial cell count.

Preoperatively, all the patients showed corneal graft transparency, normal status of the crystalline, anterior chamber depth (ACD) equal to or higher than 3.20 mm, endothelial cell count higher than 1500 cells/mm² and a stable refractive status for at least 18 months. Table 1 summarizes the patients’ details at baseline.

None of the patients had a history of recurrent or chronic uveitis, glaucoma, retinal pathologies or neurological eye diseases which could affect visual acuity.

This study was in accordance with the ethical principles for medical research involving human subjects.

<table>
<thead>
<tr>
<th>Patient</th>
<th>Age At The Time Of IOL Implantation (Years)</th>
<th>Time Between DALK And IOL Implantation (Months)</th>
<th>Preoperative Subjective Refraction (D)</th>
<th>Preoperative ECD (Cells/mm²)</th>
<th>Preoperative ACD (mm)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>26</td>
<td>314</td>
<td>−5.0−4.5×170°</td>
<td>2674</td>
<td>3.59</td>
</tr>
<tr>
<td>2</td>
<td>27</td>
<td>25.9</td>
<td>−13.0−2.0×150°</td>
<td>2404</td>
<td>3.75</td>
</tr>
<tr>
<td>3</td>
<td>37</td>
<td>34.6</td>
<td>+2.5−6.5×10°</td>
<td>1515</td>
<td>3.20</td>
</tr>
<tr>
<td>4</td>
<td>34</td>
<td>42.0</td>
<td>−6.0×30°</td>
<td>2320</td>
<td>3.25</td>
</tr>
<tr>
<td>5</td>
<td>36</td>
<td>63.3</td>
<td>−7.5−10.0×145°</td>
<td>2915</td>
<td>3.70</td>
</tr>
<tr>
<td>6</td>
<td>42</td>
<td>39.3</td>
<td>−8.0−10.0×90°</td>
<td>1835</td>
<td>4.11</td>
</tr>
<tr>
<td>7</td>
<td>24</td>
<td>30.6</td>
<td>−4.0−5.0×55°</td>
<td>1800</td>
<td>3.83</td>
</tr>
<tr>
<td>8</td>
<td>18</td>
<td>30.2</td>
<td>−7.0−7.0×145°</td>
<td>2703</td>
<td>3.88</td>
</tr>
<tr>
<td>9</td>
<td>35</td>
<td>29.6</td>
<td>−1.0−8.5×50°</td>
<td>2250</td>
<td>3.31</td>
</tr>
<tr>
<td>10</td>
<td>23</td>
<td>35.9</td>
<td>−5.5−11.0×10°</td>
<td>2994</td>
<td>3.70</td>
</tr>
<tr>
<td>11</td>
<td>26</td>
<td>29.4</td>
<td>+3.0−11.0×105°</td>
<td>2088</td>
<td>3.74</td>
</tr>
</tbody>
</table>

Table 1: Preoperative Parameters Of The Study Population
(Helsinki Declaration) and was approved by the local ethics committee of Centro Hospitalar Universitário do Porto. Informed consent was obtained from each patient prior to surgical procedure.

Outcomes Measures
The main outcomes measures were UDVA, CDVA with manifest refraction, refractive sphere, refractive cylinder, refractive spherical equivalent (SE), topographic astigmatism, corneal thickness, ACD and corneal ECD. Calculation of safety index (mean postoperative CDVA/mean preoperative CDVA) and efficacy index (mean postoperative UDVA/mean preoperative CDVA) of the procedure was conducted.

The incidence of intraoperative and postoperative complications of phakic IOLs implantation was also assessed.

For the current study, the outcomes were analysed pre-operatively and at 1 and 3 years after surgery for all the patients (n=11). In 5 patients, with a longer follow-up, the analysis was extended to 5 years after IOL implantation.

Corneal ECD was measured using specular microscope (Konan® Noncon Robo CA SP-8800) and the percentage of ECD loss per year was calculated. Topographic astigmatism, corneal thickness and ACD were measured using corneal Scheimpflug imaging (Oculus Wavelight Pentacam®).

Phakic IOLS Implanted
The Artisan® phakic toric IOL (Ophtec BV, Groningen, the Netherlands) has a convex–concave toric optic. It is a single-piece lens with an overall size of 8.5 mm and is composed of polymethyl methacrylate (PMMA). It is iris-claw fixed and has a 5-mm optical zone. The IOL is available in dioptric powers of −1.0 to −23.5 and +1.0 to +12.0 and in cylindrical powers of −1.0 to −7.5 D. The Artiflex® phakic toric IOL (Ophtec BV, Groningen, the Netherlands) is a foldable version of the Artisan® phakic IOL made of three pieces: a 6.0 mm similar convex–concave optic zone design, made of hydrophobic polysilicon, and two opposed haptics made of PMMA to enable fixation on the mid-peripheral iris. Overall length is 8 mm. The IOL is available in dioptric powers of −1.0 to −14.5 D and in cylindrical powers of −1.0 to −5.0 D.

The Artisan® phakic IOL was used when the refractive error could not be fully corrected by the Artiflex® lens.

The power calculation of the phakic IOL was obtained by Ophtec BV and approved by the surgeon. Refractive spherical error, refractive cylinder power, ACD and topographically derived keratometric dioptric values were inserted into the van der Heijde formula to calculate the dioptic power of the lens.

Surgical Technique
Previously to surgery, an iridectomy was made by a neodymium:YAG laser in all the eyes.

All surgeries were performed under general anesthesia. Pupils were constricted with pilocarpine 2% before surgery and the enclavation meridian was marked at the slit-lamp with a needle to avoid misalignments in relation to the cyclotorsion. For Artisan® lens, a 5mm length clear corneal incision was created perpendicular to the axis of lens enclavation, followed by two stab incisions located close to the clear corneal incision, directed toward the enclavation sites. For Artiflex® lens it was used a clear corneal incision of 3.2mm. The anterior chamber was filled with viscoelastic (Provisc, Alcon Laboratories, Inc., Fort Worth, TX) and the lenses were slid into the anterior chamber, using a lens’ forceps for Artisan® and a specially designed insertion spatula for Artiflex® (Opraed Artiflex® Implantation Spatula; Ophtec). Viscoelastic was re-injected and the lenses were placed in its proper position using a manipulator and fixed to the mid-peripheral iris with the enclavation needle, according to the alignment marks on the cornea. After, the viscoelastic was changed with balanced salt solution. Finally, the clear corneal incision was closed with 10–0 nylon sutures and it was injected 1 mg/0.1 mL of cefuroxime sodium in the anterior chamber.

Postoperative care consisted of topical dexamethasone 0.2% 5 times a day tapered in 3 weeks, topical fluoroquinalone 5 times a day for 2 weeks, topical nonsteroidal anti-inflammatory 5 times a day for 4 weeks and oral prednisolone 1mg/kg in a defined tapering scheme during 2 weeks.

Statistical Analysis
UDVA and CDVA were recorded on a decimal scale and converted into logarithm of the minimum angle of resolution (logMAR) values to statistical analysis. The efficacy and safety indexes were calculated using a mean value expressed on decimal scale, before conversion. Statistical analysis was done using SPSS (version 24; SPSS Inc., Chicago, IL, USA). After checking the normality of data using the Shapiro–Wilk test, the Student’s t-test for paired samples was used to compare preoperative and postoperative data when parametric analysis could be applied, and to compare it between consecutive postoperative visits. When non-parametric tests were required, the Wilcoxon ranked-sum test was used. Changes in corneal thickness,
ACD and topographic astigmatism during follow-up were compared using repeated-measures two-way analysis of variance with Bonferroni correction. A p-value of less than 0.05 was considered statistically significant. All data were expressed as mean±SD.

Results

Patient Population
The study included 11 eyes of 11 patients (4 female, 7 male) with a mean age of 29±7 years (range 17 to 42 years).

The mean time between DALK and toric phakic IOL implantation was 35.7±10.3 months (range 25.9 to 63.2 months). All sutures were removed before IOL implantation. The refractive status was stable for at least 18 months before IOL implantation. The toric Artisan lens was implanted in 8 eyes (73%) and the toric Artiflex lens in 3 eyes (27%). All patients had a minimum follow-up of 3 years after IOL implantation. In 5 patients, the analysis of the outcomes was extended up to 5 years after IOL implantation (3 eyes with Artisan lens and 2 eyes with Artiflex lens). Figure 1 illustrates one of the eyes with an Artisan IOL at 1-year follow-up.

Visual Acuity
The mean logMAR UDVA and CDVA significantly increased from preoperative to 1 year postoperative (n=11, p≤0.001 for UDVA and p=0.008), as shown in Table 2.

During follow-up, no statistically significant differences were registered in UDVA and CDVA comparing to the values registered at 1 year postoperative (p>0.05, for all comparisons, Table 2). Postoperatively, all patients gained at least 5 lines in UDVA (7.18±2.09 lines) and 63.6% of the eyes gained 2 or more lines in CDVA (Figures 2 and 3). During follow-up, only one eye lost 1 line in CDVA.

At 1 year of follow-up, 100% of the eyes had an UDVA equal or better than 0.30 logMAR, and 45.5% an UDVA equal or better than 0.10 logMAR, as compared with 0% preoperatively. At 3 years postoperatively, an UDVA and a CDVA equal or better than 0.1 logMAR was registered in 45.4% and 81.8% of eyes, respectively.

The calculated efficacy index was 1.01, 0.97 and 1.02 at 1, 3 and 5 years postoperatively, respectively. The calculated safety index was 1.24, 1.21 and 1.26 at 1, 3 and 5 years, respectively.

Refractive Outcome
The mean sphere decreased from −4.14±4.87 D (range −13.00 to +3.00 D) preoperative to −0.55±0.82 D (range −1.75 to +1.00 D) at 1 year postoperative (n=11, p=0.033) and no statistically significant differences were registered during follow-up visits (n=11, p=0.614 for 3 years follow-up; n=5, p=0.847 for 5 years follow-up). The percentage of reduction in spherical error was 73.1±31.5%.

Mean refractive cylinder significantly decreased from −7.41±3.61 D (range −11.00 to 2.00 D) preoperative to −1.00±0.95 D (range −2.50 to 0.0 D) at 1 year postoperative (n=11, p≤0.001). The mean percent reduction in refractive astigmatism was 83.8±15.8%. No significant changes were observed in refractive cylinder during follow-up (Table 2). The distribution of the postoperative refractive astigmatism achieved is shown in Figure 4. At 3 years, the refractive cylinder was within ±1.00 D in 45.4% of eyes and within ±2.00 D in 81.8% of eyes.

The mean SE refraction decreased from −8.02±4.63 D (range −0.75 to −14.00 D) preoperative to −1.02±1.07 D (range 0.0 to −2.50 D) at 1 year postoperative (n=11, p=0.001). Figure 5 shows the SE accuracy 1 year after the procedure and Figure 6 illustrates the stability of SE during 3 years follow-up.

At 3 years, mean SE refraction was within ±0.50 D in 45.4% of eyes and within ±1.50 D in 63.6% of eyes.

Table 3 resumes the visual and refractive data of eyes submitted to Artisan and Artiflex IOLs implantation at 3 years follow-up.

Endothelial Cell Count
The endothelial cell loss, as compared with preoperative, was 8.7±6.7% (n=11), 13.1±8.6% (n=11) and 14.0±20.4%...
It was registered a progressive decrease in ECD over time in operated eyes. The decline in ECD between 1 to 3 years and 3 to 5 years of follow-up was not statistically significant (Table 2).

### Table 2 Mean Preoperative And 1, 3 And 5 Years Postoperative Results Of Toric Phakic IOL Implantation After DALK: Comparative Analysis

<table>
<thead>
<tr>
<th>Outcomes</th>
<th>UDVA</th>
<th>CDVA</th>
<th>Refractive Cylinder</th>
<th>ECD (Cells/mm²)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Mean±SD</td>
<td>p-Value</td>
<td>Mean±SD</td>
<td>p-Value</td>
</tr>
<tr>
<td>Preoperative vs 1 year postoperative (n=11)</td>
<td>1.27±0.90 vs 0.16±0.15</td>
<td>≤0.001</td>
<td>0.16±0.14 vs 0.07±0.09</td>
<td>0.008</td>
</tr>
<tr>
<td>Preoperative vs 3 year postoperative (n=11)</td>
<td>1.27±0.90 vs 0.22±0.17</td>
<td>≤0.001</td>
<td>0.16±0.14 vs 0.08±0.10</td>
<td>0.011</td>
</tr>
<tr>
<td>Preoperative vs 5 year postoperative (n=5)</td>
<td>1.30±0.0 vs 0.12±0.11</td>
<td>≤0.001</td>
<td>0.14±0.09 vs 0.02±0.04</td>
<td>0.033</td>
</tr>
<tr>
<td>1 year postoperative vs 3 years postoperative (n=11)</td>
<td>0.16±0.15 vs 0.22±0.17</td>
<td>0.364</td>
<td>0.07±0.09 vs 0.08±0.10</td>
<td>0.341</td>
</tr>
<tr>
<td>1 year postoperative vs 5 years postoperative (n=5)</td>
<td>0.16±0.21 vs 0.12±0.11</td>
<td>0.757</td>
<td>0.02±0.04 vs 0.03±0.07</td>
<td>0.945</td>
</tr>
<tr>
<td>3 years postoperative vs 5 years postoperative (n=5)</td>
<td>0.14±0.09 vs 0.12±0.11</td>
<td>0.317</td>
<td>0.04±0.05 vs 0.03±0.07</td>
<td>0.317</td>
</tr>
</tbody>
</table>

Note: Significant values are shown in bold.

(n=5) at 1 year (p=0.020), 3 years (p=0.007) and 5 years postoperatively (p=0.137), respectively.

### Corneal Thickness, ACD And Topographic Astigmatism

There were no statistically significant differences in corneal thickness, ACD and topographic astigmatism over time (Table 4).

### Intraoperative And Postoperative Complications Of TICL Implantation

No severe intraoperative complications were registered. None of the eyes included developed ocular hypertension, pupillary block, acute angle-closure glaucoma or episodes of graft rejection. One of the patients (patient 3, male, 37 years old at the time of IOL implantation) had a significant decrease in ECD and ACD over the 5 years’ follow-up. This patient had the lowest ECD and ACD preoperatively. Before Artisan Iens implantation, the ECD was 1515 cells/mm² and ACD was 3.20mm. One year after surgery, the ECD had decreased to 1001 cells/mm². At this time, the patient was proposed to IOL explantation but had refused the intervention. The patient was clarified about the risk of endothelial decompensation and advised not to rub the eye. Two years after surgery, the ECD decreased to 851 cells/mm².
and at 3 years follow-up, it was registered an ECD of 840 cells/mm² and an ACD of 2.94 mm. During this time, the patient continued refusing explantation of the IOL, so was kept in close monitoring and aware of the risk of sudden endothelial decompensation. At the last appointment, it was recorded an ECD of 835 cells/mm² and an ACD of 2.91 mm. The patient maintained a transparent graft and an UDV A of 0.0 logMAR, though will be soon submitted to IOL explantation combined with phacoemulsification cataract surgery with toric IOL implantation in the capsular bag.
Several surgical options to correct refractive errors after DALK have been reported in the literature, such as PRK,\textsuperscript{13,14} LASIK,\textsuperscript{15,16} small incision lenticule extraction\textsuperscript{17} and corneal relaxing incisions.\textsuperscript{18} In addition, phakic IOLs implantation have also been satisfactorily used for visual rehabilitation after DALK in more recent reports.\textsuperscript{7,10–12} Tiveron et al\textsuperscript{12} reported the efficacy of toric phakic IOLs after DALK in 24 eyes (17 with implantation of Arti\textsuperscript{1}lex lens and 7 with Artisan lens) with a follow-up of 1 year. Comparing to this study, we obtained a higher safety and efficacy indexes (1.24 vs 1.00 and 1.01 vs 0.93, respectively) at 1 year. Moreover, in our case series the values of these indexes slightly decreased during 3 and 5 years of follow-up, so these IOLs proved to be a safety and effective procedure for visual rehabilitation with stability over time.

The first two case reports of implantation of Artisan IOL to correct ametropia\textsuperscript{10} and high astigmatism after DALK\textsuperscript{11} revealed a significant improvement in UDVA postoperatively, with all the 3 patients showing an UDVA and a CDVA of 0.1 logMAR or better at 1 year of follow-up. In this current study, the 11 patients gained at least 5 lines of UDVA at 1 year of follow-up and only one eye lost one line in CDVA throughout follow-up.

Acar et al\textsuperscript{15} also described a significant improvement in UDVA with LASIK after DALK, without eyes losing CDVA lines. Recently, Sorkin et al\textsuperscript{14} reported a significant improvement in CDVA and UDVA in 34 eyes submitted to PRK postkeratoplasty. Comparing to phakic IOLs, corneal ablation procedures carry a relatively high rate of

### Table 3 Visual And Refractive Outcomes At 3 Years Follow-Up

<table>
<thead>
<tr>
<th>Patient</th>
<th>Pre-UDVA (logMAR)</th>
<th>Pre-BDVA (logMAR)</th>
<th>Preoperative Refraction (D)</th>
<th>Type Of Toric Phakic IOL Implanted</th>
<th>3 Years Post-UDVA (logMAR)</th>
<th>3 Years Post-BDVA (logMAR)</th>
<th>3 Years Postoperative Refraction (D)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>1.30</td>
<td>0.20</td>
<td>-5.0–4.5×170°</td>
<td>Arti\textsuperscript{1}lex</td>
<td>0.30</td>
<td>0.10</td>
<td>-0.75–2.50×100°</td>
</tr>
<tr>
<td>2</td>
<td>1.30</td>
<td>0.00</td>
<td>-13.0–2.0×150°</td>
<td>Artisan</td>
<td>0.00</td>
<td>0.00</td>
<td>-0.50×170°</td>
</tr>
<tr>
<td>3</td>
<td>1.30</td>
<td>0.00</td>
<td>+2.5–6.5×10°</td>
<td>Artisan</td>
<td>0.00</td>
<td>0.00</td>
<td>-0.50×20°</td>
</tr>
<tr>
<td>4</td>
<td>1.30</td>
<td>0.10</td>
<td>-6.0×30°</td>
<td>Artisan</td>
<td>0.20</td>
<td>0.10</td>
<td>-1.00–2.00×110°</td>
</tr>
<tr>
<td>5</td>
<td>1.30</td>
<td>0.20</td>
<td>-7.5–10.0×145°</td>
<td>Artisan</td>
<td>0.20</td>
<td>0.10</td>
<td>-2.00×55°</td>
</tr>
<tr>
<td>6</td>
<td>1.30</td>
<td>0.50</td>
<td>-8.0–10.0×90°</td>
<td>Artisan</td>
<td>0.50</td>
<td>0.10</td>
<td>-1.00×70°</td>
</tr>
<tr>
<td>7</td>
<td>1.30</td>
<td>0.20</td>
<td>-4.0–5.0×55°</td>
<td>Arti\textsuperscript{1}lex</td>
<td>0.20</td>
<td>0.10</td>
<td>-1.50×35°</td>
</tr>
<tr>
<td>8</td>
<td>1.30</td>
<td>0.20</td>
<td>-7.0–7.0×145°</td>
<td>Arti\textsuperscript{1}lex</td>
<td>0.20</td>
<td>0.10</td>
<td>-1.25×110°</td>
</tr>
<tr>
<td>9</td>
<td>1.30</td>
<td>0.20</td>
<td>-1.0–8.5×50°</td>
<td>Artisan</td>
<td>0.20</td>
<td>0.10</td>
<td>-1.00×50×40°</td>
</tr>
<tr>
<td>10</td>
<td>1.30</td>
<td>0.00</td>
<td>-5.5–11.0×10°</td>
<td>Artisan</td>
<td>0.50</td>
<td>0.10</td>
<td>-3.00–0.75×0°</td>
</tr>
<tr>
<td>11</td>
<td>1.00</td>
<td>0.20</td>
<td>+3.0–11.0×105°</td>
<td>Artisan</td>
<td>0.20</td>
<td>0.10</td>
<td>+1.00–2.50×100°</td>
</tr>
</tbody>
</table>

### Table 4 Differences In Corneal Thickness, Anterior Chamber Depth And Topographic Astigmatism During Follow-Up

<table>
<thead>
<tr>
<th></th>
<th>Preoperative</th>
<th>1 Year (n=11)</th>
<th>3 Years (n=11)</th>
<th>5 Years (n=5)</th>
<th>p-Value 3 Years Follow-Up (n=11)</th>
<th>p-Value 5 Years Follow-Up (n=5)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Corneal thickness (um)</td>
<td>518±56.1</td>
<td>515±48.2</td>
<td>507±52.8</td>
<td>536±22.3</td>
<td>0.661</td>
<td>0.847</td>
</tr>
<tr>
<td>ACD (mm)</td>
<td>3.62±0.33</td>
<td>3.53±0.35</td>
<td>3.48±0.26</td>
<td>3.48±0.41</td>
<td>0.154</td>
<td>0.528</td>
</tr>
<tr>
<td>Topographic astigmatism (D)</td>
<td>6.82±2.70</td>
<td>5.88±3.49</td>
<td>5.49±3.95</td>
<td>5.24±2.10</td>
<td>0.387</td>
<td>0.089</td>
</tr>
</tbody>
</table>
complications, such as corneal graft haze and regression of treatment, offer less predictable results and may not fully correct large degrees of spherical and astigmatic refractive errors.\textsuperscript{8,19–23} The magnitude of the baseline spherical error (range +3.0 to −13.0 D) and cylindrical error (range −2.0 to −11.0 D) of this case series reflect the wide field of power range provided by phakic IOLs. These baseline refractive values were much higher than those revealed in most of the reports of LASIK postkeratoplasty, including DALK.\textsuperscript{15,16} Moreover, the percentage of reduction in refractive astigmatism (83.8±15.8\%) was higher when compared to LASIK after keratoplasty, which varies from 48\% to 88\% in different reports of the literature.\textsuperscript{19–24}

Concerning stability of the surgical procedure, there were no significant changes in refractive spherical, cylinder and SE values from 1 to 3 years and 5 years of follow-up. Also in a prospective noncomparative study with Artisan toric IOL implantation for the correction of astigmatism and anisometropia after PK, Tahzib et al\textsuperscript{8} revealed a reduction in the refractive cylinder and sphere of 88.8±29.5\% and 103.6\%±33.0\%, respectively, with the stability of the values achieved from 6 months postoperatively to 3 years of follow-up.

In this case series we presented an ECD loss of 8.7±6.7\% (n=11), 13.1±8.6\% (n=11) and 14.0±20.4\% (n=5) (p=0.137) at 1, 3 and 5 years of follow-up, respectively. The percentage of ECD loss at 1 year was slightly higher than the published by Tiveron et al.\textsuperscript{12} However, these results were favorable when compared to those reported by Tahzib et al\textsuperscript{8} in eyes with Artisan IOL after PK (Table 5). This could be explained by the fact that ECD decay is higher after PK comparing to DALK, as shown in several studies comparing both techniques.\textsuperscript{2,3,25} In our center, the mean ECD loss after DALK was 5.3\%±4.8\% at 1 year after surgery. Comparing to eyes without keratoplasty, the ECD loss in the current series is higher than the revealed by other studies for Artisan\textsuperscript{26–28} and Artiflex IOLs\textsuperscript{29,30} (Table 5).

Despite our small sample size, we observed a progressive endothelial cell loss at each time point as compared with preoperative cell density values. The observed mean ECD loss could be explained by the lens itself, by the normal ECD loss after DALK or by the combination of both. Nevertheless, it was not registered a significantly loss between 1 year postoperatively to 3 and 5 years. It is consistent with other reports which describe a more significant decline in ECD during the first 12–24 months after phakic IOLs implantation.\textsuperscript{31,32}

In this case series, there was one patient who revealed a significant decrease in ECD and ACD over time, reaching values lower than 1000 cells/mm\textsuperscript{2} and 3.00 mm, respectively. It should be noted that the preoperative

<table>
<thead>
<tr>
<th>Author, Year</th>
<th>Technique</th>
<th>Sample Size (n= Eyes)</th>
<th>Country</th>
<th>ECD Loss</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tiveron et al,\textsuperscript{12} 2017</td>
<td>Artisan and Artiflex IOLs after DALK</td>
<td>24</td>
<td>Spain</td>
<td>1 year: 6.10%</td>
</tr>
<tr>
<td>Tahzib et al,\textsuperscript{8} 2006</td>
<td>Artisan IOL after PK</td>
<td>34</td>
<td>The Netherlands</td>
<td>1 year: 21.2% (n=34) 3 years: 30.4% (n=18)</td>
</tr>
<tr>
<td>Cheng,\textsuperscript{25} 2011</td>
<td>PK vs DALK</td>
<td>56</td>
<td>The Netherlands</td>
<td>1 year: 27.7% PK vs 12.9% DALK</td>
</tr>
<tr>
<td>Pop,\textsuperscript{26} 2004</td>
<td>Artisan IOL without keratoplasty</td>
<td>765</td>
<td>Canada</td>
<td>1 year: 0.87%</td>
</tr>
<tr>
<td>Hashemi,\textsuperscript{27} 2013</td>
<td>Artisan IOL without keratoplasty</td>
<td>53</td>
<td>Iran</td>
<td>1 year: 3.04%</td>
</tr>
<tr>
<td>Silva,\textsuperscript{28} 2008</td>
<td>Artisan IOL without keratoplasty</td>
<td>26</td>
<td>USA</td>
<td>5 years: 14.0%</td>
</tr>
<tr>
<td>Guerin et al,\textsuperscript{29} 2014</td>
<td>Artiflex IOL without keratoplasty</td>
<td>28</td>
<td>Ireland</td>
<td>1 year: 6.17%</td>
</tr>
<tr>
<td>Jonker,\textsuperscript{30} 2018</td>
<td>Artiflex IOL without keratoplasty</td>
<td>188</td>
<td>The Netherlands</td>
<td>5 years: 10.2%</td>
</tr>
<tr>
<td>Our Center, 2018</td>
<td>DALK</td>
<td>47</td>
<td>Portugal</td>
<td>1 year: 5.3%</td>
</tr>
<tr>
<td>Current study, 2019</td>
<td>Toric phakic IOLs after DALK</td>
<td>11</td>
<td>Portugal</td>
<td>1 year: 8.7% (n=11) 3 years: 13.1% (n=11) 5 years: 14.0% (n=5)</td>
</tr>
</tbody>
</table>
values of ECD and ACD of this patient were the lowest of the sample. The decision to implant phakic IOLs in patients with preoperative endothelial cell counts lower than those recommended by Ophtec BV is based on the fact that, for these patients, with low BCVA due to high ametropias after corneal transplantation, the implantation of phakic IOLs is not considered a premium refractive surgery. Instead, the main purpose of the procedure is to try to provide a better visual acuity in patients who had already tried other less invasive refractive options, without success. This decision is made together with the patient after carefully explaining and discussing all the complications of the surgery.

The patient will be submitted to IOL explantation combined with cataract surgery, that, still, highlights one of the advantages of phakic IOLs implantation, which is the reversibility of the procedure, in contrast to corneal ablation procedures.

To the best of our knowledge, this is the first case series describing long-term results of toric phakic IOLs after DALK. We demonstrate that these IOLs are an effective and stable procedure for management high ametropia after DALK. However, we observed a continuing endothelial cell loss postoperatively, which assumed to be higher than those reported in eyes with phakic IOLs implantation without DALK. Additional long-term analysis with larger samples are needed to confirm these results and for them to be used as guidance for clinical practice.

Disclosure
The authors have no conflict of interest to report and have not received any financial support for the research provided.

References


